235 results
DEFA14A
KA
Kineta Inc
26 Apr 24
Additional proxy soliciting materials
4:03pm
Materials
Soliciting Material under §240.14a12
KINETA, INC.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy … materials.
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.
Your Vote Counts Logo KINETA, INC.2023 Annual
D
KA
Kineta Inc
20 Oct 23
$2.89 mm in options / securities to be acquired, 1 investor
1:04pm
in all instances or due to the nature of the offering that is the subject of this Form D, States cannot
routinely require offering materials under … this undertaking or otherwise and can require offering materials only to the
extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.
8-K
EX-10.1
4zagc57eq fb3t
5 Oct 23
Kineta, Inc. Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:05pm
424B5
zhs7 llft
5 Oct 23
Prospectus supplement for primary offering
10:47am
DEFA14A
gbtvea7t
28 Apr 23
Additional proxy soliciting materials
5:08pm
8-K
EX-10.1
2oenseua19yz64il
21 Apr 23
Kineta, Inc. Announces $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
5:16pm
424B5
5ws3riwe j3y
21 Apr 23
Prospectus supplement for primary offering
5:14pm
D
04bld2
29 Dec 22
$30.00 mm in equity, sold $7.50 mm, 17 investors
3:12pm
8-K
EX-99.6
xl0 eaepib6fh
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
8-K
EX-99.5
b18t7plcl7x
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
8-K
EX-99.4
g9m0 n79y
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
425
y5j8ms c7i7h9ezo
6 Dec 22
Business combination disclosure
4:04pm
8-K
3mnkwwo98oghe
6 Dec 22
Regulation FD Disclosure
4:02pm